Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) generates news at the intersection of oncology drug development and artificial intelligence–driven molecular discovery. Public updates highlight the company’s efforts to improve outcomes for cancer patients treated with radiation therapy, as well as its ownership and deployment of the Molecule.ai platform, a pharmaceutical software AI-driven system for molecular discovery and early-stage drug development.
Recent news releases describe several key themes. Shuttle Pharma has reported on its historical Phase II clinical trial of Ropidoxuridine (IPdR) in glioblastoma patients undergoing radiation therapy, including enrollment progress and tolerability data, and later on its decision to discontinue those clinical trials and initiate winddown activities in coordination with its contract research organization and clinical sites. These items provide context on the evolution of the company’s oncology pipeline and its strategic reassessment of clinical programs.
Another major news focus is the acquisition and integration of Molecule.ai. Press releases and 8-K filings detail a binding term sheet, asset purchase agreement and closing of the transaction under which a Shuttle Pharma subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Coverage explains how the platform supports molecular property prediction, drug-target interaction modeling, cross-property evaluation and structured reasoning, and how Shuttle Pharma aims to use these capabilities to augment its drug discovery and development activities.
News items also address capital markets and regulatory developments, such as a private placement involving a pre-funded warrant, related S-1 and S-1/A registration statements for resale of the underlying shares, and communications regarding Nasdaq listing requirements and a reverse stock split undertaken as part of a compliance initiative. Together, these disclosures offer investors and observers a view into SHPH’s scientific programs, AI platform strategy, financing transactions and listing status.
For readers following SHPH news, the company’s updates provide ongoing insight into its transition from a radiation-sensitizer–focused clinical-stage pharmaceutical profile toward a combined biotechnology and AI-driven molecular discovery business model.
Shuttle (NASDAQ: SHPH) entered a definitive merger to acquire United Dogecoin and will issue Series B-1 preferred stock to United Dogecoin holders, subject to shareholder approval. A concurrent $11 million PIPE is expected to close May 4, 2026. United Dogecoin plans up to 3,000 ElphaPex rigs delivering up to 43,200 GH/s (~1.5% global Dogecoin hashrate) within 60 days and anticipates low-cost, renewable energy and preferential hardware access.
Shuttle (NASDAQ: SHPH) agreed to acquire United Dogecoin and will merge it into a wholly owned subsidiary, supported by an $11 million PIPE expected to close May 4, 2026. United Dogecoin intends to order up to 3,000 ElphaPex mining rigs for up to 43,200 GH/s (about 1.5% of global Dogecoin hashrate).
Transaction consideration includes 8,000 Series B-1 convertible preferred (≈32,258,064 common shares on conversion) and contingent pre-funded warrants tied to operational milestones; PIPE investors receive Series B-2 securities and warrants convertible upon shareholder approval.
Shuttle Pharmaceuticals (NASDAQ:SHPH) on March 27, 2026 announced a major upgrade to its molecule.ai platform, adding generative and predictive models plus a preview of an autonomous, multi-agent AI system for scientific workflows.
The release emphasizes multi-step reasoning, multimodal data ingestion, and orchestration to accelerate therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on March 26, 2026 announced a major expansion of its molecule.ai platform, adding new predictive and generative models and a preview of an autonomous, multi-agent AI system for scientific workflows.
The update enables multi-step reasoning, multimodal data ingestion, and prioritization of gene–disease and compound–target relationships to accelerate early therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a public offering to issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares for aggregate gross proceeds of approximately $3.5 million.
The offering is expected to close on or about March 9, 2026, with E.F. Hutton & Co. as exclusive placement agent. The company intends to use up to $1.5 million for marketing and the remainder for working capital and general corporate purposes. The securities are being offered under an effective Form S-1 (File No. 333-293363) registration statement.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on January 13, 2026 highlighted Utah's new pilot allowing AI to authorize prescription refills and explained why that regulatory milestone matters for its Molecule.ai drug‑discovery platform. The release links Utah's AI refill program to time and cost savings in healthcare and argues Molecule.ai can similarly cut drug discovery bottlenecks by reducing time to identify candidates, lowering failed‑experiment costs, and automating repetitive screening.
The company says Molecule.ai uses agentic AI with uncertainty quantification, human‑in‑the‑loop workflows, and explainable models to enable oversight and scale while aiming to accelerate R&D and improve access to therapies.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced it closed the acquisition of substantially all assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai for a total purchase price of $8 million payable in cash and Shuttle common stock, plus a contingent $2 million in cash and stock tied to performance milestones.
An initial $3 million was paid at closing; remaining consideration will be delivered over time and, for contingent payments, subject to milestone achievement and Molecule's election of cash or equity. Shuttle said the acquisition adds an AI molecular modeling and predictive analytics platform to its drug discovery and development capabilities.
Shuttle Pharmaceuticals (NASDAQ: SHPH) entered a securities purchase agreement with a single investor to raise approximately $2.5 million in gross proceeds via the sale of a pre-funded warrant that can be exercised into up to 625,156 shares at an effective price of $4.00 per share. The price is described as above-the-market under Nasdaq rules. The Offering is expected to close on or about November 4, 2025, subject to customary closing conditions.
WestPark Capital is the exclusive placement agent. The company intends to use net proceeds for marketing, general corporate purposes and working capital and has agreed to file registration statement(s) to cover resale of shares issuable upon exercise of the pre-funded warrant.
Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for approximately $10 million, payable in a mix of cash and common stock with timing and ratios tied to performance milestones. Molecule.ai provides an AI platform designed to reason with scientific data, predict molecular interactions, and iterate designs in real time. Shuttle positions the deal as a strategic shift from a chemistry-focused biotech to a hybrid platform company aiming to scale discovery through perpetual machine learning.
Shuttle Pharmaceuticals (NASDAQ:SHPH) signed a definitive letter of intent on October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for $10 million, payable in cash and Shuttle common stock with milestone‑contingent timing and mix. Molecule.ai provides an Agentic AI Mode that automates drug discovery workflows, including drug‑target interaction simulation and molecular property reasoning, which Shuttle says can shorten early R&D timelines by months. Shuttle plans to integrate the platform with its oncology programs to accelerate discovery of radiation sensitizers and create a self‑learning discovery engine with potential cross‑therapeutic licensing options.